News

Endometrial cancer survival lowest in Non-Hispanic black women


 

FROM CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION

References

For aggressive endometrial cancer subtypes, Non-Hispanic black women had mortality rates more than 1.5-fold higher than those of non-Hispanic white women diagnosed with the same subtype of endometrial cancer and at the same stage of disease, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

Dr. Michele Cote

Dr. Michele Cote

Using cancer incidence and mortality data from the Surveillance, Epidemiology, End Results (SEER) database, Dr. Michele Cote of Wayne State University, Detroit, and her colleagues examined patient records from 120,513 endometrial cancer cases diagnosed from 2000 to 2011 in the United States. Compared with non-Hispanic white women, non-Hispanic black women had poorer survival at every stage of diagnosis regardless of endometrial cancer subtype, while 5-year survival rates were similar or higher among Asian and Hispanic women compared with non-Hispanic white women (Cancer Epidemiol Biomarkers Prev. 2015;Aug 19. doi: 10.1158/1055-9965.EPI-15-0316).

However, endometrial cancer incidence rates increased among all racial and ethnic groups over the 12-year study period, with rates increasing as much as 2.5 percent per year among non-Hispanic black women and Asian women.

“Prior studies have suggested that disparities in outcomes from endometrial cancer might be explained by differences in tumor subtype or stage at diagnosis, but our data suggest that disparities persist even when these factors are controlled for,” Dr. Cote said in a statement.

Click here for the full article.

mbock@frontlinemedcom.com

Recommended Reading

EULAR: Women with RA have increased cervical neoplasia rates
MDedge Hematology and Oncology
Serial CA-125 measurements better for ovarian cancer screening
MDedge Hematology and Oncology
Olaparib for BRCA-mutated advanced ovarian cancer
MDedge Hematology and Oncology
BMI-based dosing suboptimal for ovarian cancer
MDedge Hematology and Oncology
Selecting the right contraception method for cancer patients
MDedge Hematology and Oncology
ASCO supports endometrial cancer RT guidelines with some qualifications
MDedge Hematology and Oncology
Medicare adds HPV test for cervical cancer screening
MDedge Hematology and Oncology
Age and tumor site impact outcome in rare ovarian cancer
MDedge Hematology and Oncology
Intraperitoneal chemo still underused for ovarian cancer
MDedge Hematology and Oncology
Intestinal obstruction risk increased in some childhood cancer survivors
MDedge Hematology and Oncology